Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible

This Perspective discusses the actions needed to improve accessibility of glucagon-like peptide-1 (GLP-1) receptor agonists, especially in low- and middle-income countries, after their addition to the World Health Organization’s (WHO) Model List of Essential Medicines.